Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay

Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment. The post Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay appeared first on Investor's Business Daily.